- Home
- NKTR vs SVII Comparison
NKTR vs SVII Comparison
Compare NKTR & SVII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTR
- SVII
- Stock Information
- Founded
- NKTR 1990
- SVII 2021
- Country
- NKTR United States
- SVII United States
- Employees
- NKTR N/A
- SVII N/A
- Industry
- NKTR Biotechnology: Pharmaceutical Preparations
- SVII Blank Checks
- Sector
- NKTR Health Care
- SVII Finance
- Exchange
- NKTR Nasdaq
- SVII Nasdaq
- Market Cap
- NKTR 247.9M
- SVII 252.5M
- IPO Year
- NKTR 1994
- SVII 2022
- Fundamental
- Price
- NKTR $1.01
- SVII $11.23
- Analyst Decision
- NKTR Buy
- SVII
- Analyst Count
- NKTR 4
- SVII 0
- Target Price
- NKTR $4.00
- SVII N/A
- AVG Volume (30 Days)
- NKTR 1.8M
- SVII 134.4K
- Earning Date
- NKTR 11-07-2024
- SVII 01-01-0001
- Dividend Yield
- NKTR N/A
- SVII N/A
- EPS Growth
- NKTR N/A
- SVII N/A
- EPS
- NKTR N/A
- SVII N/A
- Revenue
- NKTR $93,137,000.00
- SVII N/A
- Revenue This Year
- NKTR N/A
- SVII N/A
- Revenue Next Year
- NKTR N/A
- SVII N/A
- P/E Ratio
- NKTR N/A
- SVII $12.50
- Revenue Growth
- NKTR 5.53
- SVII N/A
- 52 Week Low
- NKTR $0.42
- SVII $10.78
- 52 Week High
- NKTR $1.93
- SVII $11.70
- Technical
- Relative Strength Index (RSI)
- NKTR 30.88
- SVII 34.95
- Support Level
- NKTR $1.33
- SVII $11.20
- Resistance Level
- NKTR $1.07
- SVII $11.37
- Average True Range (ATR)
- NKTR 0.09
- SVII 0.05
- MACD
- NKTR -0.04
- SVII -0.04
- Stochastic Oscillator
- NKTR 6.26
- SVII 6.00
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.